B+
Bull case
0%
Probability
Target price
$78.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
HAE
HaemoneticsFNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The post-earnings bull read is that Haemonetics closed FY26 with better-than-feared core growth: Q4 adjusted EPS slightly beat the Zacks-based snapshot, FY27 guidance implies re-acceleration, and Hospital plus Plasma are carrying the portfolio while Vivasure adds another interventional growth leg.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Adjusted gross margin also fell 50 bps, with less favorable mix and tariff impacts called out in the earnings release [#8-K-2026-05-07].
Momentum
94
Value
63
Sentiment
17
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $66.00 · Bull $78.00 · Bear $46.00Analysis 2026-05-09; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $108.40
Why
Momentum94 · Δ7d +0.6
Value63 · Δ7d -0.0
Sentiment17 · Δ7d +2.5
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Adjusted gross margin also fell 50 bps, with less favorable mix and tariff impacts called out in the earnings release [#8-K-2026-05-07].
- • Cash on hand declined to $245.4 million, primarily due to the Vivasure acquisition and share repurchases, reducing balance-sheet cushion if execution slips [#8-K-2026-05-07].
- • The bear read is that the quarter still contained real quality issues beneath the headline: GAAP EPS was a loss, gross margin fell on Attune-related inventory charges and tariff pressure, Blood Center remains a drag, and proof of a sustained interventional recovery is still incomplete.
Catalyst clock
2026-08-01
Q4/FY26 print and FY27 guide support a near-term reset
Lead driver: Value · See fundamentals
Momentum
94
9% active weight
Current posture
7d trendFlat
Δ7d
+0.6
Δ21d
+1.1
Value
63
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-1.2
Sentiment
17
62% active weight
Current posture
7d trendImproving
Δ7d
+2.5
Δ21d
+3.7
Why this grade
Composite grade F. Momentum 94.3 / Value 62.6 / Sentiment 16.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-09. Scenario method
Most likely
B
Base case
1%
Probability
Target price
$66.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$46.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$4.11B
Beta
0.28
Shares Out
45.5M
P/E (TTM)
24.0
P/S (TTM)
2.89
P/FCF (TTM)
18.08
Rev YoY
+5.6%
EPS YoY
+2.6%
Gross Margin
+55.9%
Op Margin
+18.4%
Net Debt
$1.03B
Current Ratio
3.08
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data